Trial · NCT04923529
TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
NCT04923529, Phase 2, Completed, The University of Hong Kong
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma. Trials, record NCT04923529. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04923529
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
- NCT number
- NCT04923529
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 28 participants, actual
- Lead sponsor
- The University of Hong Kong
- Conditions
- Pancreas Cancer
- Interventions
- TAS 102
- First posted
- 2021-06-11
- Last updated
- 2025-07-18
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 16-week progression-free survival (PFS) rate | From the date of informed consent to radiographically documented progression according to RECIST 1.1, assessed up to 16 weeks | The percentage of study population alive and without progression (according to RECIST 1.1) at 16 weeks from the date of informed consent |
| Secondary | Progression-free Survival (PFS) | from the date of informed consent to radiographically documented progression according to RECIST 1.1 or death from any cause, whichever occurs first, assessed up to 3 years | PFS is measured from the date of informed consent to radiographically documented progression according to RECIST 1.1 or death from any cause (whichever occurs first). Participants alive and without disease progression or lost to follow up will be censored at the date of their last radiographic assessment. |
| Secondary | Time to progression (TTP) | from the date of informed consent to radiographically documented progression according to RECIST 1.1, assessed up to 3 years | TTP is measured from the date of informed consent to radiographically documented progression according to RECIST 1.1. Participants death and without disease progression, alive without disease progression, or lost to follow-up will be censored at the date of their last radiographic assessment |
| Secondary | Overall survival (OS) | from the date of informed consent to the date of death from any cause, assessed up to 5 years | OS is measured from date of informed consent to the date of death from any cause. Participants alive or lost to follow-up will be censored at the date of their last radiographic assessment |
| Secondary | Objective response rate (ORR) | From the date of first study treatment to radiographically documented complete response or partial response according to RECIST 1.1, assessed up to 3 years | The percentage of patients with radiologically complete or partial response as determined by the Investigator according to RECIST version 1.1. |
| Secondary | Disease control rate (DCR) | from the date of first study treatment to radiographically documented complete response, partial response, or stable disease according to RECIST 1.1, assessed up to 3 years | The percentage of patients with radiologically complete response, partial response, or stable disease as determined by the Investigators according to RECIST version 1.1 |
| Secondary | Duration of response (DoR) | from the date of documentation of tumor response to radiographically documented progression according to RECIST 1.1, assessed up to 3 years | DoR is the time from documentation of tumor response to radiographically documented disease progression |
| Secondary | Time to deterioration of ECOG performance status | from the date of informed consent to the first date on which ECOG performance status scores 2 or higher, assessed up to 3 years | Time from date of informed consent until the first date on which ECOG performance status score of 2 or higher was recorded |
| Secondary | Time to deterioration of quality of life | from the date of informed consent to recorded decrease of 10 points or more in EORTC QLQ-C30 assessment, assessed up to 3 years | Decrease from baseline of 10 points or more on the EORTC QLQ-C30 maintained for two consecutive assessments or a decrease of 10 points or more in one assessment followed by death from any cause within 3 weeks |
| Secondary | Incidence of Study-Related Adverse Events [Safety and Tolerability] | from the date of first study treatment to occurrence of study-related adverse events based on NCI-CTCAE 5, assessed up to 3 years | Incidence, nature, and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE 5) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers36
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04923529
GET https://conductscience.org/api/trials/v1/NCT04923529/papers?page=2